Gujarat Magazine

DelveInsight’s, “HDAC Inhibitors Pipeline Insights, 2023,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in HDAC Inhibitors Inhibitors pipeline landscape. It covers the HDAC Inhibitors pipeline drug profiles, including HDAC Inhibitors clinical trials and nonclinical stage products. It also covers the HDAC Inhibitors pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the HDAC Inhibitors pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, HDAC Inhibitors clinical trials studies, HDAC Inhibitors NDA approvals (if any), and product development activities comprising the technology, HDAC Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key takeaways from the HDAC Inhibitors Pipeline Report

• DelveInsight’s HDAC Inhibitors Pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for HDAC Inhibitors treatment.

• The leading HDAC Inhibitors Companies includes Roche, Takeda San Diego, Italfarmaco, Sulfidris, MethylGene, EpiGen Pharmaceuticals, DAC Research, Karus Therapeutics, Xynomic Pharmaceuticals, Medivir, Mirati Therapeutics, Janssen Pharmaceuticals, and others.

• Promising HDAC Inhibitors Pipeline Therapies such as ITF2357, Quisinostat, Paclitaxel, Carboplatin, CHR-3996, 4SC-202, Dexamethasone, Vorinostat, and others.

• The HDAC Inhibitors companies and academics are working to assess challenges and seek opportunities that could influence HDAC Inhibitors R&D. The HDAC Inhibitors pipeline therapies under development are focused on novel approaches for HDAC Inhibitors.

To explore more information on the latest breakthroughs in the HDAC Inhibitors Pipeline treatment landscape of the report, click here @ HDAC Inhibitors Pipeline Outlook

HDAC Inhibitors Overview

The histone deacetylase inhibitors (HDACi) are a group of small molecules that target histone deacetylases (HDACs) by inhibiting their activity. HDACi have a long history of use in neurology and psychiatry as antiepileptics and mood stabilizers. More recently, they have been investigated as possible treatments for cancer. Histone deacetylase (HDAC) inhibitors are a relatively new class of anti-cancer agents that play important roles in epigenetic or non-epigenetic regulation, inducing death, apoptosis, and cell cycle arrest in cancer cells. Eighteen human HDAC enzymes have been identified and classified into four groups based on their homology with yeast HDACs.

HDAC Inhibitors Emerging Drugs Profile

• Givinostat: Italfarmaco

Givinostat is an investigational drug discovered through Italfarmaco’s internal research and development efforts in collaboration with Lorenzo Puri (SanfordBurnhamPrebys Medical Research Institute, San Diego, formerly Santa Lucia Foundation, Rome) and his team, and partnerships with Telethon and Parent Project aps. It is being evaluated for safety and efficacy for the treatment of Duchenne- and Becker- Muscular Dystrophy.

Givinostat inhibits histone deacetylases (HDACs). HDACs are enzymes that prevent gene translation by changing the three-dimensional folding of DNA in the cell. Studies show that Duchenne patients have higher than normal HDAC levels, which may prevent muscle regeneration, and also trigger inflammation. In the company’s clinical study in DMD boys aged seven to less than 11 years, Givinostat was observed to slow disease progression, significantly increase muscle mass and reduce the amount of fibrotic tissue. Givinostat treatment also significantly reduced muscle tissue necrosis and fatty replacement, two additional parameters related to disease progression (Bettica et al., Neuromuscular Disorder 2016).

For further information, refer to the detailed HDAC Inhibitors Unmet Needs, E HDAC Inhibitors Market Drivers, and HDAC Inhibitors Market Barriers, click here for HDAC Inhibitors Ongoing Clinical Trial Analysis

HDAC Inhibitors Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the Histone deacetylase (HDAC) Inhibitors. The companies which have their Histone deacetylase (HDAC) Inhibitors drug candidates in the most advanced stage, i.e. phase II include, Italfarmaco.

HDAC Inhibitors Pipeline: Phases

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Request a sample and discover the recent advances in HDAC Inhibitors Ongoing Clinical Trial Analysis and Medications, click here @ HDAC Inhibitors Treatment Landscape

Scope of the HDAC Inhibitors Pipeline Report

• Coverage- Global

• HDAC Inhibitors Companies- Roche, Takeda San Diego, Italfarmaco, Sulfidris, MethylGene, EpiGen Pharmaceuticals, DAC Research, Karus Therapeutics, Xynomic Pharmaceuticals, Medivir, Mirati Therapeutics, Janssen Pharmaceuticals, and others

• HDAC Inhibitors Pipeline Therapies- ITF2357, Quisinostat, Paclitaxel, Carboplatin, CHR-3996, 4SC-202, Dexamethasone, Vorinostat, and others.

• HDAC Inhibitors Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for HDAC Inhibitors Market Drivers and E HDAC Inhibitors Market Barriers, click here @ HDAC Inhibitors Unmet Needs and Analyst Views

Table of Content

1. Introduction
2. Executive Summary
3. Histone deacetylase (HDAC) Inhibitors: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Histone deacetylase (HDAC) Inhibitors – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Histone deacetylase (HDAC) Inhibitors Collaboration Deals
9. Mid Stage Products (Phase II)
10. Givinostat: Italfarmaco
11. Early Stage Products (Phase I)
12. Drug Name: Company Name
13. Pre-clinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Histone deacetylase (HDAC) Inhibitors Key Companies
17. Histone deacetylase (HDAC) Inhibitors Key Products
18. Histone deacetylase (HDAC) Inhibitors- Unmet Needs
19. Histone deacetylase (HDAC) Inhibitors- Market Drivers and Barriers
20. Histone deacetylase (HDAC) Inhibitors- Future Perspectives and Conclusion
21. Histone deacetylase (HDAC) Inhibitors Analyst Views
22. Histone deacetylase (HDAC) Inhibitors Key Companies
23. Appendix

Got Queries? Find out the related information on HDAC Inhibitors Mergers and acquisitions, HDAC Inhibitors Licensing Activities @ HDAC Inhibitors Emerging Drugs, and Recent Trends

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services